ALDR News and Press, Alder BioPharmaceuticals Inc. From 08/22/19

Quick Take Satsuma Pharmaceuticals ( STSA ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on the development of a treatment of acute migraine headache. STSA has begun Phase 3 trials and expects to pu...

Eli Lilly ( LLY ) announced that it had achieved a positive outcome in its phase 3 study that used Emgality as a preventative treatment for patients with chronic and episodic migraines. The company is off to a decent start in sales for Emgality, but this latest outcome might help it to i...

The following slide deck was published by Alder BioPharmaceuticals, Inc. in conjunction with this Read more ...

Alder BioPharmaceuticals, Inc. (ALDR) Q2 2019 Results Conference Call August 6, 2019 05:00 PM ET Company Participants Michael Horowicz - Stern Investor Relations Bob Azelby - Chief Executive Officer Paul Streck - Chief Medical Officer Nadia Dac - Chief Commercial Officer Carl...

Alder Bio (NASDAQ: ALDR ): Q2 GAAP EPS of -$0.72 beats by $0.22 . More news on: Alder BioPharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Data presented at American Academy of Neurology and American Headache Society Annual Meetings continue to support eptinezumab’s differentiated clinical profile and impact on quality of life measures   Core commercial leadership team secured, including field payer team, in a...

BOTHELL, Wash., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Direc...

BOTHELL, Wash., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder’s president and chief executive office...

BOTHELL, Wash., July 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its second quarter 2019 financial and operating ...

            - Posters presented at the 2019 American Headache Society meeting highlight eptinezumab’s safety profile and suppression of calcitonin gene-related peptide (CGRP) -              - N...